Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus

Current Diabetes Reports

Volumn 10, Issue 3, 2010, Pages 184-191

  Tripathy, Devjit ^a   Chavez, Alberto O ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adipokines; Free fatty acids; Incretins; Insulin resistance; Insulin secretory defects; Mitochondrial dysfunction; Type 2 diabetes mellitus

Indexed keywords

ADIPOCYTOKINE; AMYLIN; FATTY ACID; GLUCOSE; INCRETIN; INSULIN; MELATONIN RECEPTOR; MELATONIN RECEPTOR 1B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BRAIN TISSUE; CELL FUNCTION; CYTOKINE RELEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GLUCOSE METABOLISM; HORMONE ACTION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIVER PARENCHYMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS;

EID: 77956392948     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0115-5     Document Type: Review

References (58)

1. Defronzo RA: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795. This recent comprehensive review describes in detail all new players in the pathogenesis of T2DM.
2. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
3. DeFronzo RA, Tripathy D: Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32 (Suppl 2):S157-S163.
4. DeFronzo RA, Gunnarsson R, Bjorkman O, et al.: Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 1985, 76:149-155.
5. Bonadonna RC, Groop L, Kraemer N, et al.: Obesity and insulin resistance in humans: a dose-response study. Metabolism 1990, 39:452-459.
6. Gulli G, Ferrannini E, Stern M, et al.: The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992, 41:1575-1586.
7. Mari A, Wahren J, DeFronzo RA, Ferrannini E: Glucose absorption and production following oral glucose: comparison of compartmental and arteriovenous-difference methods. Metabolism 1994, 43:1419-1425.
8. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al.: Early metabolic defects in persons at increased risk for non-insulindependent diabetes mellitus. N Engl J Med 1989, 321:337-343.
9. Tripathy D, Lindholm E, Isomaa B, et al.: Familiality of metabolic abnormalities is dependent on age at onset and phenotype of the type 2 diabetic proband. Am J Physiol Endocrinol Metab 2003, 285:E1297-E1303.
10. Tripathy D, Carlsson AL, Lehto M, et al.: Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 2000, 43:1476-1483.
11. Defronzo RA, Banerji MA, Bray GA, et al.: Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia 2010, 53:435-445.
12. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787-794.
13. Sriwijitkamol A, Christ-Roberts C, Berria R, et al.: Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Diabetes 2006, 55:760-767.
14. Reyna SM, Ghosh S, Tantiwong P, et al.: Elevated toll-like receptor 4 expression and signaling in muscle from insulinresistant subjects. Diabetes 2008, 57:2595-2602.
15. Mullen E, Ohlendieck K: Proteomic profiling of non-obese type 2 diabetic skeletal muscle. Int J Mol Med 2010, 25:445-458.
16. Tripathy D, Eriksson KF, Orho-Melander M, et al.: Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in type 2 diabetes. Diabetologia 2004, 47:782-793.
17. Li S, Brown MS, Goldstein JL: Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 2010, 107:3281-3282.
18. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
19. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005,115:1111-1119.
20. Galic S, Oakhill JS, Steinberg GR: Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010, 316:129-139.
21. Karastergiou K, Mohamed-Ali V: The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 2010, 318:69-78.
22. Gerozissis K: Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur J Pharmacol 2008, 585:38-49.
23. Tschritter O, Preissl H, Hennige AM, et al.: The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A 2006, 103:12103-12108.
24. Richardson DK, Kashyap S, Bajaj M, et al.: Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem 2005, 280:10290-10297.
25. Chavez AO, Kamath S, Jani R, et al.: Effect of short-term free fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals. J Clin Endocrinol Metab 2010, 95:422-429.
26. Hwang H, Bowen BP, Lefort N, et al.: Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes. Diabetes 2010, 59:33-42.
27. Ozcan U, Cao Q, Yilmaz E, et al.: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
28. Ozcan U, Yilmaz E, Ozcan L, et al.: Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
29. Boden G, Duan X, Homko C, et al.: Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 2008, 57:2438-2444.
30. Belfort R, Mandarino L, Kashyap S, et al.: Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005, 54:1640-1648.
31. Boden G, Lebed B, Schatz M, et al.: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001, 50:1612-1617.
32. Tripathy D, Mohanty P, Dhindsa S, et al.: Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52:2882-2887.
33. DeFronzo RA: Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004, 88:787-835, ix.
34. Gastaldelli A, Ferrannini E, Miyazaki Y, et al.: Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004, 47:31-39.
35. Abdul-Ghani MA, Jenkinson CP, Richardson DK, et al.: Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006, 55:1430-1435.
36. Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
37. Tripathy D, Carlsson M, Almgren P, et al.: Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000, 49:975-980.
38. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
39. Lencioni C, Lupi R, Del Prato S: Beta-cell failure in type 2 diabetes mellitus. Curr Diab Rep 2008, 8:179-184.
40. Eizirik DL, Cardozo AK, Cnop M: The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008, 29:42-61.
41. Cnop M, Igoillo-Esteve M, Cunha DA, et al.: An update on lipotoxic endoplasmic reticulum stress in pancreatic beta-cells. Biochem Soc Trans 2008, 36:909-915.
42. Matsuda T, Kido Y, Asahara S, et al.: Ablation of C/EBPbeta alleviates ER stress and pancreatic beta cell failure through the GRP78 chaperone in mice. J Clin Invest 2010, 120:115-126.
43. Palotay JL, Howard CF Jr: Insular amyloidosis in spontaneously diabetic nonhuman primates. Vet Pathol Suppl 1982, 7:181-192.
44. Ritzel RA, Meier JJ, Lin CY, et al.: Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 2007, 56:65-71.
45. Guardado-Mendoza R, Davalli AM, Chavez AO, et al.: Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A 2009, 106:13992-13997. This describes in detail the pancreatic islet morphology and the role of IAPP and a-cell hyperplasia in islets.
46. Drucker DJ: Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007, 30:1335-1343.
47. Nauck MA, Meier JJ: The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. Diabetologia 2007, 50:2413-2416.
48. Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
49. Nauck MA, Heimesaat MM, Orskov C, et al.: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
50. Elahi D, McAloon-Dyke M, Fukagawa NK, et al.: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994, 51:63-74.
51. Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
52. Vilsboll T, Krarup T, Madsbad S, Holst JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002, 45:1111-1119.
53. Altshuler D, Hirschhorn JN, Klannemark M, et al.: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26:76-80.
54. Deeb SS, Fajas L, Nemoto M, et al.: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287.
55. Sladek R, Rocheleau G, Rung J, et al.: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
56. Lyssenko V, Lupi R, Marchetti P, et al.: Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007, 117:2155-2163. This is the best study thus far describing in detail the physiology of the TCF7L2 gene.
57. Lyssenko V, Nagorny CL, Erdos MR, et al.: Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009, 41:82-88.
58. Saxena R, Hivert MF, Langenberg C, et al.: Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010, 42:142-148.